Discover comprehensive details about Tolterodine, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...

Review the side-effects of Tolterodine as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

A total of 1022 patients (818 females, 204 males) aged 21 to 93 years were randomised into the study. Patients were enrolled in North America (53%), Europe (42%) and Australia (5%). These represented ...

The International Continence Society(ICS) has defined overactive bladder(OAB) as urinary urgency with orwithout urge incontinence, usually with frequencyand nocturia, in the absence ofproven infection ...

As Table II indicates, oxybutynin XL is the dominant therapeutic option. Not only does it provide superior effectiveness results compared with tolterodine IR, it also leads to lower overall costs.

New York, November 4, 2004 – Combination therapy with Pfizer Inc's DETROL® LA (tolterodine tartrate extended release capsules) and an alpha blocker, a standard treatment for enlarged prostate, was ...

Although anticholinergic medications are widely used to treat urinary incontinence in the elderly, the fact that their use may be associated with memory loss and visual hallucinations has not been ...

Tolterodine tartrate 2mg, 4mg; ext-rel caps. Swallow whole. 4mg once daily; may decrease to 2mg once daily. Concomitant strong CYP3A4 inhibitors (eg, ketoconazole, clarithromycin, ritonavir), or ...

To assess the safety and efficacy of a combination of doxazosin and tolterodine in men with BOO, and BOO plus OABS. On the basis of URODYNAMIC ASSESSMENT, men with lower urinary tract symptoms were ...

All patients treated with tolterodine ER,oxybutynin ER, or oxybutynin IR who hadvalid information on pharmacy claims wereselected for the persistency and compliance analyses. Matched pairs of ...

BAUDETTE, Minn., Jan. 24, 2020 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Tolterodine Extended-Release Capsules, 2 mg and 4 mg. The current annual U ...